<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-8040 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-8040</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-8040</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-148.html">extraction-schema-148</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of neuronal populations within the visual (occipital) cortex that show selective vulnerability or resistance to amyloid‑β plaques or tau tangles in dementia, including details on cell type, cortical layer, subregion, pathology type, reported mechanisms, experimental models, quantitative measures, species, disease stage, and any contrasting findings.</div>
                <p><strong>Paper ID:</strong> paper-67772023</p>
                <p><strong>Paper Title:</strong> Opposing Roles of apolipoprotein E in aging and neurodegeneration</p>
                <p><strong>Paper Abstract:</strong> This study investigates how APOE modulates neuronal function integrity during normal aging and in the context of amyloidosis. This work demonstrates that APOE is a necessary partner of Aβ-dependent neuronal dysfunction and synaptotoxicity but also preserves neuronal network during aging.</p>
                <p><strong>Cost:</strong> 0.013</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e8040.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e8040.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of neuronal populations within the visual (occipital) cortex that show selective vulnerability or resistance to amyloid‑β plaques or tau tangles in dementia, including details on cell type, cortical layer, subregion, pathology type, reported mechanisms, experimental models, quantitative measures, species, disease stage, and any contrasting findings.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>V1 visually-responsive neurons (APP/PS1 + ApoE)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Visually-evoked neurons in primary visual cortex (V1) of APP/PS1 mice expressing endogenous murine ApoE</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Neurons in the mouse primary visual cortex that show impaired visually-evoked calcium responses and synaptic dysfunction in APP/PS1 amyloidosis mice expressing endogenous ApoE; deficits are associated with dense, Methoxy-XO4+ amyloid plaques and local synaptic loss and glial activation.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>OPPOSING ROLES OF APOLIPOPROTEIN E IN AGING AND NEURODEGENERATION</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>neuronal_population</strong></td>
                            <td>Visually-evoked neurons (single-cell calcium-imaged neurons) in visual cortex</td>
                        </tr>
                        <tr>
                            <td><strong>cortical_subregion</strong></td>
                            <td>Primary visual cortex (V1)</td>
                        </tr>
                        <tr>
                            <td><strong>cortical_layer</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>vulnerability_status</strong></td>
                            <td>vulnerable</td>
                        </tr>
                        <tr>
                            <td><strong>pathology_type</strong></td>
                            <td>amyloid‑β plaques</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_source</strong></td>
                            <td>APP/PS1 transgenic mouse (with endogenous murine ApoE)</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_method</strong></td>
                            <td>In vivo two-photon calcium imaging of visually-evoked responses; immunohistochemistry (Methoxy-XO4) for plaques; array tomography for synaptic density; NeuN staining for neuronal density</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_measure</strong></td>
                            <td>In-text report: increased fraction of visually non-/dysfunctional neurons in APP/PS1 compared with controls (exact APP/PS1 % not provided); reported comparator percentages for other groups: WT 4.32 ± 1.27% off-responders; APOEnull 4.68 ± 1.19%; APP/PSEN1/APOEnull 3.2 ± 0.84%; global Aβ load reported as comparable to APP/PS1;ApoE-null but plaques are dense and Methoxy-XO4+ in ApoE-expressing APP/PS1 mice; synaptic loss near plaques detected by array tomography (numeric values not provided in excerpt). Ages examined typically 8–10 months (adult) for APP/PS1 functional deficits.</td>
                        </tr>
                        <tr>
                            <td><strong>reported_mechanism</strong></td>
                            <td>Presence of ApoE promotes formation/stabilization of dense, neurotoxic Aβ aggregates and recruits/activates glia around plaques, increasing local synaptotoxicity; ApoE–Aβ interactions may change Aβ conformation into more harmful oligomeric species and facilitate microglial/astrocyte responses that contribute to neuronal dysfunction.</td>
                        </tr>
                        <tr>
                            <td><strong>associated_genes_proteins</strong></td>
                            <td>Apolipoprotein E (ApoE), amyloid‑β (Aβ40/Aβ42), APP/PS1 transgene context, Methoxy‑XO4 (plaque label), NeuN (neuronal marker); microglial/astrocytic markers implied (microgliosis/astrogliosis).</td>
                        </tr>
                        <tr>
                            <td><strong>species</strong></td>
                            <td>Mus musculus</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage</strong></td>
                            <td>Early/moderate amyloid-bearing stage in APP/PS1 model (adult, ~8–10 months)</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Overall Aβ burden not strictly predictive of toxicity; APP/PS1;ApoE-null mice have comparable global Aβ but different plaque morphology (diffuse, non-neuritic) and show rescued function; literature reports that ApoE deletion can cause vascular BBB defects and cognitive deficits in some studies, complicating interpretation of ApoE's role. Some prior work shows removal of ApoE ameliorates amyloid pathology in other FAD models.</td>
                        </tr>
                        <tr>
                            <td><strong>reference_citation</strong></td>
                            <td>10.26508/lsa.201900325</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Opposing Roles of apolipoprotein E in aging and neurodegeneration', 'publication_date_yy_mm': '2019-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e8040.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e8040.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of neuronal populations within the visual (occipital) cortex that show selective vulnerability or resistance to amyloid‑β plaques or tau tangles in dementia, including details on cell type, cortical layer, subregion, pathology type, reported mechanisms, experimental models, quantitative measures, species, disease stage, and any contrasting findings.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>V1 visually-responsive neurons (APP/PS1;ApoE-null)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Visually-evoked neurons in primary visual cortex (V1) of APP/PS1 mice lacking murine ApoE</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Neurons in V1 of APP/PS1 mice with genetic ablation of murine ApoE show preserved visually-evoked calcium responses and rescued synaptic density near plaques despite overall similar total Aβ levels, associated with diffuse/non‑neuritic plaque morphology and markedly reduced plaque-associated glial recruitment.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>OPPOSING ROLES OF APOLIPOPROTEIN E IN AGING AND NEURODEGENERATION</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>neuronal_population</strong></td>
                            <td>Visually-evoked neurons (single-cell calcium-imaged neurons) in visual cortex</td>
                        </tr>
                        <tr>
                            <td><strong>cortical_subregion</strong></td>
                            <td>Primary visual cortex (V1)</td>
                        </tr>
                        <tr>
                            <td><strong>cortical_layer</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>vulnerability_status</strong></td>
                            <td>resistant (relative resistance to Aβ-dependent dysfunction)</td>
                        </tr>
                        <tr>
                            <td><strong>pathology_type</strong></td>
                            <td>amyloid‑β plaques (diffuse/non-neuritic phenotype)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_source</strong></td>
                            <td>APP/PS1;ApoE-null transgenic mouse (complete murine ApoE knock-out)</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_method</strong></td>
                            <td>In vivo two-photon calcium imaging of visually-evoked responses; Methoxy‑XO4 plaque labeling; array tomography for synaptic density; immunohistochemistry for glial markers</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_measure</strong></td>
                            <td>Reported percent of off-responding neurons in APP/PSEN1/APOEnull: 3.2 ± 0.84%; global Aβ levels stated as comparable to APP/PS1 but plaque morphology shifted toward diffuse/non-neuritic deposits; 'drastic decrease' in microglial and astrocyte recruitment to plaques reported (no absolute counts provided in excerpt).</td>
                        </tr>
                        <tr>
                            <td><strong>reported_mechanism</strong></td>
                            <td>Absence of ApoE shifts Aβ aggregation toward diffuse, less neurotoxic species and prevents ApoE-mediated formation/stabilization of neurotoxic Aβ conformers and glial recruitment, thereby protecting local synapses and neuronal function.</td>
                        </tr>
                        <tr>
                            <td><strong>associated_genes_proteins</strong></td>
                            <td>Apolipoprotein E (absent), amyloid‑β (Aβ40/Aβ42), Methoxy‑XO4 (dense plaque marker), microglial/astrocytic markers (not specified), APP/PS1 transgene.</td>
                        </tr>
                        <tr>
                            <td><strong>species</strong></td>
                            <td>Mus musculus</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage</strong></td>
                            <td>Early/moderate amyloid-bearing stage in APP/PS1 model (adult, ~8–10 months) after ApoE ablation</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Although plaque-associated gliosis is reduced, gross microglial density between WT and ApoE-null mice showed no striking difference on gross inspection; some previous studies show that ApoE deletion ameliorates amyloid pathology in other FAD models but interpretation may differ by model and human vs murine ApoE isoforms.</td>
                        </tr>
                        <tr>
                            <td><strong>reference_citation</strong></td>
                            <td>10.26508/lsa.201900325</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Opposing Roles of apolipoprotein E in aging and neurodegeneration', 'publication_date_yy_mm': '2019-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e8040.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e8040.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of neuronal populations within the visual (occipital) cortex that show selective vulnerability or resistance to amyloid‑β plaques or tau tangles in dementia, including details on cell type, cortical layer, subregion, pathology type, reported mechanisms, experimental models, quantitative measures, species, disease stage, and any contrasting findings.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>V1 neurons (aged ApoE-null)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Visually-evoked neurons in primary visual cortex (V1) of aged ApoE-null mice (no amyloid pathology)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>In aged (18–20 month) mice lacking ApoE but without amyloid pathology, visually-evoked neuronal tuning/performance is impaired, indicating a deleterious effect of complete ApoE absence on neuronal function with aging.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>OPPOSING ROLES OF APOLIPOPROTEIN E IN AGING AND NEURODEGENERATION</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>neuronal_population</strong></td>
                            <td>Visually-evoked neurons (single-cell calcium-imaged neurons) in visual cortex</td>
                        </tr>
                        <tr>
                            <td><strong>cortical_subregion</strong></td>
                            <td>Primary visual cortex (V1)</td>
                        </tr>
                        <tr>
                            <td><strong>cortical_layer</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>vulnerability_status</strong></td>
                            <td>vulnerable (age-dependent dysfunction in absence of ApoE)</td>
                        </tr>
                        <tr>
                            <td><strong>pathology_type</strong></td>
                            <td>no amyloid pathology in these animals (age-related dysfunction independent of Aβ/tau)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_source</strong></td>
                            <td>ApoE-null mouse (aged, 18–20 months), wild-type comparator</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_method</strong></td>
                            <td>In vivo two-photon calcium imaging of visually-evoked responses; NeuN immunostaining and gross cortical thickness assessment (no overt neuronal loss detected by these gross measures)</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_measure</strong></td>
                            <td>Age groups specified: 'adult' 8–10 months and 'aged' 18–20 months; reported impairment in visually-evoked neuronal responses in aged ApoE-null mice (no precise numeric effect sizes provided in excerpt); NeuN staining and cortical thickness showed no gross neuronal loss.</td>
                        </tr>
                        <tr>
                            <td><strong>reported_mechanism</strong></td>
                            <td>ApoE normally supports neuronal homeostasis (lipid metabolism, BBB integrity, myelin integrity, response to stress); its absence sensitizes neurons to age-related stressors possibly via vascular dysfunction, lipid dysregulation, or other homeostatic roles, leading to functional impairment in aged mice.</td>
                        </tr>
                        <tr>
                            <td><strong>associated_genes_proteins</strong></td>
                            <td>Apolipoprotein E (absent), NeuN (neuronal marker); vascular/BBB-associated molecules and markers referenced in literature (e.g., tight junctions, fibrinogen, MMP‑9) though not measured in this study's excerpt.</td>
                        </tr>
                        <tr>
                            <td><strong>species</strong></td>
                            <td>Mus musculus</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage</strong></td>
                            <td>Aging (18–20 months), no amyloid pathology</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Literature reports on ApoE-null mice are mixed: several studies report cognitive and vascular deficits in ApoE-/- mice (BBB leakage, perivascular IgG/fibrinogen, tight junction loss), while other studies did not consistently find behavioral deficits; current study did not detect gross neuronal loss despite functional impairment.</td>
                        </tr>
                        <tr>
                            <td><strong>reference_citation</strong></td>
                            <td>10.26508/lsa.201900325</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Opposing Roles of apolipoprotein E in aging and neurodegeneration', 'publication_date_yy_mm': '2019-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>ApoE facilitates the microglial response to amyloid plaque pathology <em>(Rating: 2)</em></li>
                <li>ApoE isoform-dependent modulation of amyloid‑β aggregation and toxicity <em>(Rating: 1)</em></li>
                <li>Oligomeric amyloid‑β associates with postsynaptic densities and correlates with excitatory synapse loss near plaques <em>(Rating: 2)</em></li>
                <li>Lowering apolipoprotein E levels after Aβ seeding modulates plaque size and toxicity <em>(Rating: 2)</em></li>
                <li>Knockout of ApoE ameliorates amyloid pathology in PDAPP mice <em>(Rating: 1)</em></li>
            </ol>
        </div>

        <div class="section">
            <h2>Extracted Data (Debug)</h2>
            <pre><code>{
    "id": "extraction-result-8040",
    "paper_id": "paper-67772023",
    "extraction_schema_id": "extraction-schema-148",
    "extracted_data": [
        {
            "name_short": "V1 visually-responsive neurons (APP/PS1 + ApoE)",
            "name_full": "Visually-evoked neurons in primary visual cortex (V1) of APP/PS1 mice expressing endogenous murine ApoE",
            "brief_description": "Neurons in the mouse primary visual cortex that show impaired visually-evoked calcium responses and synaptic dysfunction in APP/PS1 amyloidosis mice expressing endogenous ApoE; deficits are associated with dense, Methoxy-XO4+ amyloid plaques and local synaptic loss and glial activation.",
            "citation_title": "OPPOSING ROLES OF APOLIPOPROTEIN E IN AGING AND NEURODEGENERATION",
            "mention_or_use": "use",
            "neuronal_population": "Visually-evoked neurons (single-cell calcium-imaged neurons) in visual cortex",
            "cortical_subregion": "Primary visual cortex (V1)",
            "cortical_layer": null,
            "vulnerability_status": "vulnerable",
            "pathology_type": "amyloid‑β plaques",
            "evidence_source": "APP/PS1 transgenic mouse (with endogenous murine ApoE)",
            "experimental_method": "In vivo two-photon calcium imaging of visually-evoked responses; immunohistochemistry (Methoxy-XO4) for plaques; array tomography for synaptic density; NeuN staining for neuronal density",
            "quantitative_measure": "In-text report: increased fraction of visually non-/dysfunctional neurons in APP/PS1 compared with controls (exact APP/PS1 % not provided); reported comparator percentages for other groups: WT 4.32 ± 1.27% off-responders; APOEnull 4.68 ± 1.19%; APP/PSEN1/APOEnull 3.2 ± 0.84%; global Aβ load reported as comparable to APP/PS1;ApoE-null but plaques are dense and Methoxy-XO4+ in ApoE-expressing APP/PS1 mice; synaptic loss near plaques detected by array tomography (numeric values not provided in excerpt). Ages examined typically 8–10 months (adult) for APP/PS1 functional deficits.",
            "reported_mechanism": "Presence of ApoE promotes formation/stabilization of dense, neurotoxic Aβ aggregates and recruits/activates glia around plaques, increasing local synaptotoxicity; ApoE–Aβ interactions may change Aβ conformation into more harmful oligomeric species and facilitate microglial/astrocyte responses that contribute to neuronal dysfunction.",
            "associated_genes_proteins": "Apolipoprotein E (ApoE), amyloid‑β (Aβ40/Aβ42), APP/PS1 transgene context, Methoxy‑XO4 (plaque label), NeuN (neuronal marker); microglial/astrocytic markers implied (microgliosis/astrogliosis).",
            "species": "Mus musculus",
            "disease_stage": "Early/moderate amyloid-bearing stage in APP/PS1 model (adult, ~8–10 months)",
            "counter_evidence": "Overall Aβ burden not strictly predictive of toxicity; APP/PS1;ApoE-null mice have comparable global Aβ but different plaque morphology (diffuse, non-neuritic) and show rescued function; literature reports that ApoE deletion can cause vascular BBB defects and cognitive deficits in some studies, complicating interpretation of ApoE's role. Some prior work shows removal of ApoE ameliorates amyloid pathology in other FAD models.",
            "reference_citation": "10.26508/lsa.201900325",
            "uuid": "e8040.0",
            "source_info": {
                "paper_title": "Opposing Roles of apolipoprotein E in aging and neurodegeneration",
                "publication_date_yy_mm": "2019-02"
            }
        },
        {
            "name_short": "V1 visually-responsive neurons (APP/PS1;ApoE-null)",
            "name_full": "Visually-evoked neurons in primary visual cortex (V1) of APP/PS1 mice lacking murine ApoE",
            "brief_description": "Neurons in V1 of APP/PS1 mice with genetic ablation of murine ApoE show preserved visually-evoked calcium responses and rescued synaptic density near plaques despite overall similar total Aβ levels, associated with diffuse/non‑neuritic plaque morphology and markedly reduced plaque-associated glial recruitment.",
            "citation_title": "OPPOSING ROLES OF APOLIPOPROTEIN E IN AGING AND NEURODEGENERATION",
            "mention_or_use": "use",
            "neuronal_population": "Visually-evoked neurons (single-cell calcium-imaged neurons) in visual cortex",
            "cortical_subregion": "Primary visual cortex (V1)",
            "cortical_layer": null,
            "vulnerability_status": "resistant (relative resistance to Aβ-dependent dysfunction)",
            "pathology_type": "amyloid‑β plaques (diffuse/non-neuritic phenotype)",
            "evidence_source": "APP/PS1;ApoE-null transgenic mouse (complete murine ApoE knock-out)",
            "experimental_method": "In vivo two-photon calcium imaging of visually-evoked responses; Methoxy‑XO4 plaque labeling; array tomography for synaptic density; immunohistochemistry for glial markers",
            "quantitative_measure": "Reported percent of off-responding neurons in APP/PSEN1/APOEnull: 3.2 ± 0.84%; global Aβ levels stated as comparable to APP/PS1 but plaque morphology shifted toward diffuse/non-neuritic deposits; 'drastic decrease' in microglial and astrocyte recruitment to plaques reported (no absolute counts provided in excerpt).",
            "reported_mechanism": "Absence of ApoE shifts Aβ aggregation toward diffuse, less neurotoxic species and prevents ApoE-mediated formation/stabilization of neurotoxic Aβ conformers and glial recruitment, thereby protecting local synapses and neuronal function.",
            "associated_genes_proteins": "Apolipoprotein E (absent), amyloid‑β (Aβ40/Aβ42), Methoxy‑XO4 (dense plaque marker), microglial/astrocytic markers (not specified), APP/PS1 transgene.",
            "species": "Mus musculus",
            "disease_stage": "Early/moderate amyloid-bearing stage in APP/PS1 model (adult, ~8–10 months) after ApoE ablation",
            "counter_evidence": "Although plaque-associated gliosis is reduced, gross microglial density between WT and ApoE-null mice showed no striking difference on gross inspection; some previous studies show that ApoE deletion ameliorates amyloid pathology in other FAD models but interpretation may differ by model and human vs murine ApoE isoforms.",
            "reference_citation": "10.26508/lsa.201900325",
            "uuid": "e8040.1",
            "source_info": {
                "paper_title": "Opposing Roles of apolipoprotein E in aging and neurodegeneration",
                "publication_date_yy_mm": "2019-02"
            }
        },
        {
            "name_short": "V1 neurons (aged ApoE-null)",
            "name_full": "Visually-evoked neurons in primary visual cortex (V1) of aged ApoE-null mice (no amyloid pathology)",
            "brief_description": "In aged (18–20 month) mice lacking ApoE but without amyloid pathology, visually-evoked neuronal tuning/performance is impaired, indicating a deleterious effect of complete ApoE absence on neuronal function with aging.",
            "citation_title": "OPPOSING ROLES OF APOLIPOPROTEIN E IN AGING AND NEURODEGENERATION",
            "mention_or_use": "use",
            "neuronal_population": "Visually-evoked neurons (single-cell calcium-imaged neurons) in visual cortex",
            "cortical_subregion": "Primary visual cortex (V1)",
            "cortical_layer": null,
            "vulnerability_status": "vulnerable (age-dependent dysfunction in absence of ApoE)",
            "pathology_type": "no amyloid pathology in these animals (age-related dysfunction independent of Aβ/tau)",
            "evidence_source": "ApoE-null mouse (aged, 18–20 months), wild-type comparator",
            "experimental_method": "In vivo two-photon calcium imaging of visually-evoked responses; NeuN immunostaining and gross cortical thickness assessment (no overt neuronal loss detected by these gross measures)",
            "quantitative_measure": "Age groups specified: 'adult' 8–10 months and 'aged' 18–20 months; reported impairment in visually-evoked neuronal responses in aged ApoE-null mice (no precise numeric effect sizes provided in excerpt); NeuN staining and cortical thickness showed no gross neuronal loss.",
            "reported_mechanism": "ApoE normally supports neuronal homeostasis (lipid metabolism, BBB integrity, myelin integrity, response to stress); its absence sensitizes neurons to age-related stressors possibly via vascular dysfunction, lipid dysregulation, or other homeostatic roles, leading to functional impairment in aged mice.",
            "associated_genes_proteins": "Apolipoprotein E (absent), NeuN (neuronal marker); vascular/BBB-associated molecules and markers referenced in literature (e.g., tight junctions, fibrinogen, MMP‑9) though not measured in this study's excerpt.",
            "species": "Mus musculus",
            "disease_stage": "Aging (18–20 months), no amyloid pathology",
            "counter_evidence": "Literature reports on ApoE-null mice are mixed: several studies report cognitive and vascular deficits in ApoE-/- mice (BBB leakage, perivascular IgG/fibrinogen, tight junction loss), while other studies did not consistently find behavioral deficits; current study did not detect gross neuronal loss despite functional impairment.",
            "reference_citation": "10.26508/lsa.201900325",
            "uuid": "e8040.2",
            "source_info": {
                "paper_title": "Opposing Roles of apolipoprotein E in aging and neurodegeneration",
                "publication_date_yy_mm": "2019-02"
            }
        }
    ],
    "potentially_relevant_new_papers": [
        {
            "paper_title": "ApoE facilitates the microglial response to amyloid plaque pathology",
            "rating": 2,
            "sanitized_title": "apoe_facilitates_the_microglial_response_to_amyloid_plaque_pathology"
        },
        {
            "paper_title": "ApoE isoform-dependent modulation of amyloid‑β aggregation and toxicity",
            "rating": 1,
            "sanitized_title": "apoe_isoformdependent_modulation_of_amyloidβ_aggregation_and_toxicity"
        },
        {
            "paper_title": "Oligomeric amyloid‑β associates with postsynaptic densities and correlates with excitatory synapse loss near plaques",
            "rating": 2,
            "sanitized_title": "oligomeric_amyloidβ_associates_with_postsynaptic_densities_and_correlates_with_excitatory_synapse_loss_near_plaques"
        },
        {
            "paper_title": "Lowering apolipoprotein E levels after Aβ seeding modulates plaque size and toxicity",
            "rating": 2,
            "sanitized_title": "lowering_apolipoprotein_e_levels_after_aβ_seeding_modulates_plaque_size_and_toxicity"
        },
        {
            "paper_title": "Knockout of ApoE ameliorates amyloid pathology in PDAPP mice",
            "rating": 1,
            "sanitized_title": "knockout_of_apoe_ameliorates_amyloid_pathology_in_pdapp_mice"
        }
    ],
    "cost": 0.01303125,
    "model_str": "gpt-5-mini"
}</code></pre>
        </div>
        <div class="section">
            <h2>Paper</h2>
            <div class="paper-content"><p>OPPOSING ROLES OF APOLIPOPROTEIN E IN AGING AND NEURODEGENERATION Review Timeline
Submission Date: 2019-01-29</p>
<p>Eloise Hudry 
Jacob Klickstein 
Claudia Cannavo 
Rosemary Jackson 
Alona Muzikansky 
Sheetal Gandhi 
David Urick 
Taylie Sargent 
Lauren Wrobleski 
Allyson Roe 
Steven Hou 
Kishore Kuchibhotla 
Rebecca Betensky 
Tara Spires-Jones 
Bradley Hyman 
OPPOSING ROLES OF APOLIPOPROTEIN E IN AGING AND NEURODEGENERATION Review Timeline
Submission Date: 2019-01-2910.26508/lsa.201900325Corresponding author(s): Eloise Hudry, Massachusetts General Hospital -Harvard Editorial Decision: 2019-01-30 Revision Received: 2019-02-05 Accepted: 2019-02-06 Scientific Editor: Andrea Leibfried Transaction Report: (Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. The original formatting of letters and referee reports may not be reflected in this compilation.) Please note that the manuscript was previously reviewed at another journal and the reports were taken into account in inviting a revision for publication at Life Science Alliance prior to submission to Life Science Alliance.
Referee #1:This manuscript was designed to determine the effect of endogenous mouse (m)-apoE on aging in wildtype (wt) mice and AD-related pathology in APP/PS1 mice. Thus, the comparison is wt vs. APOE-/-vs. APP/PS1 vs. APP/PS1/APOE-/-. The readouts include visually-evoked calcium transients, amyloid deposition, aggregation state of A, levels of extracted A40 and A42, levels of excitatory or inhibitory neurotransmitter receptors at the synapse (including adjacent to plaques), neuroinflammation (astrocytosis and microgliosis). The manuscript is carefully written and the experiments are well designed and executed. The major problem is conceptual.1. In wt mice, removing endogenous m-APOE has primarily a negative effect, including "lack of APOE independently triggers mild neuronal dysfunction with age". This makes intuitive sense as m-apoE is interacting with the endogenous expression levels of other mouse proteins.Answer:We agree with this statement, which emphasizes on the important role of apoE in the maintenance of neuronal homeostasis and function (as further demonstrated in our study).2. In contrast to wt mice, in FAD-transgenic (Tg) mice, m-apoE is interacting with overexpression of human (h)-APP/PS1 and the resulting h-A40 and A42. As far back as Bales in 1997, knock-out of m-APOE from PDAPP mice improved the A pathology of that FAD-Tg mouse model. Most recently, Ulrich, JEM, 2018 reported that "ApoE facilitates the microglial response to amyloid plaque pathology", but this paper was, again, describing the effects of removing m-APOE from a FAD-Tg mouse model. Overall, that is the same result reported herein. "We concluded that m-APOE is a necessary factor participating in amyloid-dependent loss of network integrity". The assumption remains that m-apoE, which differs from h-apoE by ~100/299 amino acids, has an essentially toxic interaction with h-APP/PS1 and the resulting h-A40 and A42 and the pathology they induce. However, when h-APOE is expressed in FAD-Tg/APOE-/-, even the expression of APOE4 improves the pathology compared to APOE-/-. For this reason, experiments designed to determine the difference between the presence and absence of m-apoE would seem not as relevant as the difference between the h-apoE isoforms (with a single amino acid difference) on a FAD-Tg mouse background. Indeed, experimental FAD/hAPOE models have produced data relevant to the differences in AD risk caused by APOE4 and APOE2.Answer:We are well aware of the limitations of using mouse models to mimic complex neurological diseases and of the value of comparing the impact of the different human APOE isoforms as compared with murine apoE. However, the present study was essentially designed to get a better understanding of the fundamental impact of the apoE protein on neuronal function. This work was not primarily designed to address how apoE affect amyloid pathology or microglial phenotype, as those aspects have already been extensively investigated (as stated by the reviewer). Rather, knowing the many functions of apoE in the brain, we aimed to assess how its absence would drive changes in the ability of neurons to integrate and respond to sensory stimuli. This work does not provide further information about which specific aspect of apoE biology (on lipid metabolism, neuroinflammation, blood brain barrier integrity, etc) drives the APP/PS1;Apoenull mice). How does this impact neuronal function in APP/PS1;Apoenull mice? One would assume that neuronal damage would be greater in areas with high Abeta intensity. Authors should take this into account and re-analyze their current data in relation to neuronal function and synaptic integrity along with glial activation.Answer:We have demonstrated in the present study that, even though the global load of amyloid is comparable in APP/PS1 and APP/PS1/apoE-null mice, the amyloid deposits observed in APP/PS1/apoe-null mice are mostly "diffuse and non-neuritic", similarly to the deposits observed in non-demented aged individuals. Because of this striking change in the aggregation state of Abeta peptides, it is not very surprising that no deficit in the visually-evoked neuronal responses are observed in AD Tg mice lacking apoE. By contrast, the plaques detected in AD transgenic mice expressing apoE are dense (labelled by Methoxy-XO4) and potentially much more neurotoxic, which is why pronounced deficits are observed in those mice. In our manuscript, we extensively discussed the fact that there is no strong correlation between the overall amyloid burden and Abeta-dependent neurotoxicity. Rather, the state of Abeta aggregation matters.7. Does ApoE exert differential effects on neuronal numbers during early neurotoxic stage (e.g. loss) and later neuroprotective stage in the aging brain?Answer: We did not perform an extensive evaluation of the density of neurons in the brains of apoE-null or APP/PS1/apoE-null mice, but we did not notice any sign of neuronal loss after gross evaluation of the cortex of those mouse models (evaluation of the cortical thickness or of the intensity of NeuN immunostaining). The initial characterization of the APP/PS1 mouse model also did not report any overt neuronal loss (PMID 14645205).8. What is the efficiency of ApoE knockdown in the present model as measured for example by apoE levels in plasma and CSF?Answer:The apoE knockdown mouse model used in this study (available at the Jackson Laboratory) has been initially developed by disrupting the endogenous mouse apoE gene in embryonic stem cells. This mouse line is homozygous for this genetic modification and therefore does not express any detectable apoE mRNA or protein across the entire organism. As such, apoE levels in plasma and CSF are not detectable. 9.Figures 1-3do not indicate whether adult (8-10 month-old) or aged (18-20 month-old) mice were studied. These details should be indicated in the figure legends.</p>
<p>rescue of neuronal dysfunction in the context of AD Tg mice or leads to neuronal dysfunction in aged APOE-null mice in absence of amyloid pathology.</p>
<ol>
<li>Even more concerning is the conclusion that "down-regulating ApoE expression as a possible therapeutic approach to alleviate Aβ-dependent neuronal impairment." Perhaps this would be an appropriate therapeutic approach for a FAD-Tg mouse. But without the interactions between h-APP/PS1 and the h-apoE isoforms, this is a potentially dangerous conclusion.</li>
</ol>
<p>Answer:</p>
<p>We respectfully disagree with this statement. Indeed, our study shows that the absence of apoE improves Abeta-related neuronal dysfunction and synaptic loss, which clearly establish apoE as an important partner of Abeta to induce neurotoxicity. Based on those readouts, hypothesizing that down-regulating apoE expression in patients could be a way to alleviate Abeta-dependent neurotoxic effects and be beneficial to AD patients makes sense. A recent paper published in 2017 by the group of Dr. Holtzman at WashU has attempted such therapeutic approach in APOE4 AD Tg mice using antisense oligonucleotides targeting apoE (PMID 29216448). This work showed that a significant decrease of the levels of apoE mRNA and protein could be achieved after intracerebroventricular injection of ASO, and that lowering apoE after Aβ seeding modulates plaque size and toxicity (similarly as the present study).</p>
<p>Referee #2:</p>
<p>In this manuscript, the authors try to address the question whether loss of Apoe had any detrimental consequences (in wild type mice) and can reduce Abeta amyloid damage (in APP/PS1 mice). The authors use an experimental paradigm based on measuring neuronal activation in the visual cortex. They show that "the absence of APOE largely abrogates Aβdependent neuronal dysfunction in a mouse model of amyloidosis" and that the "complete lack of APOE itself can impact tuning performances". The data support well their conclusions, although the effects seen are not high. Further, they show that lack of Apoe is beneficial at the level of amyloid-induced synaptic damage (loss of Apoe rescues the decrease in synaptic density). A very interesting finding is in the last part of the paper, where the authors show that lack of Apoe abrogates astrogliosis and microgliosis around amyloid plaques. The study does not conclusively address whether Apoe loss is a viable therapy, but is an interesting report nonetheless adding to the knowledge of this field.</p>
<p>Remarks:</p>
<p>The authors should provide information about power calculations for the number of mice that they have decided to use.</p>
<p>Answer:</p>
<p>We have not performed a power calculation beforehand for the present work but evaluated the number of animals needed based on a previous work from our lab using a similar experimental setting in a model of tauopathy (in vivo recording of visual-evoked neuronal responses in wild-type and Tg4510 mice, Kuchibhotla KV et al. PNAS. PMID 24368848). Another paper published in 2012 reported visual-dependent decline of neuronal function in a mouse model of amyloidosis with comparable features as the one used in the present work (Grienberger C et al. Nat Comm. 2012, PMID: 22491322). The results of those seminal studies reached significance with a number of mice of 3-15 mice/group, as compared with 5 &lt;n &lt;11 animals per group in our work.</p>
<p>Authors should refrain from using "trend" when a comparison does not show a p value below their set threshold (e.g. page 4 when commenting Figure EV3, or page 5 last paragraph).</p>
<p>Answer:</p>
<p>We have now corrected this issue and disambiguate those statements for more clarity.</p>
<p>On page 5, first line, authors say that "non-responder" neurons were almost absent in all groups (except APP/PS1-Apoenull), however looking at Figure 2C there seem to be cells in all groups, particularly in Apoenull group. Authors should reword this sentence, and possibly have numbers of percentages of non-responders for each group in the text, as it is difficult to extrapolate from the plot in 2C.</p>
<p>Answer:</p>
<p>We have now rephrased this sentence and included the percentages of "off-responders" for each experimental group: "Intriguingly, the percentage of off-responding neurons was much lower in all the other groups considered (wild-type: 4.321.27%; APOEnull: 4.681.19%; APP/PSEN1/APOEnull: 3.20.84%), and especially in APP/PSEN1/APOEnull mice lacking apoe expression, suggesting that APOEnull mice normalizes an alteration from normal physiology observed in APP/PSEN1 mice."</p>
<p>Loss of Apoe causes a drastic decrease in the number of microglia and astrocytes recruited at plaques. Could the authors add a quantification of microglia and astrocytes in wild type and wild type-Apoenull? It would be quite interesting to add the information about whether loss of Apoe in APP/PS1 mice results in a completely abolished recruitment (i.e. there is no difference with a general astrocyte / microglia distribution in the parenchyma of wild type mice, meaning that in absence of Apoe plaques are gliosis-inert).</p>
<p>Answer:</p>
<p>The gross evaluation of the density of microglial cells between wild-type and apoE-null mice did not reveal any striking difference, and therefore we did not perform a complete stereological evaluation to confirm those findings.</p>
<p>Referee #3:</p>
<p>Hudry et al. investigated apolipoprotein E (ApoE) effects on neuronal function and synaptic integrity in adult wild-type, Apoenull, APP/PS1 and APP/PS1;Apoenull mice. Using two-photon calcium imaging to record visually-evoked responses, authors first found that genetic removal of Apoe improved neuronal responses in 8-10 months of age APP/PS1 mice. In addition, these mice developed fewer parenchymal amyloid plaques with a reduced amount of synaptic loss -using high-resolution array tomography -and activated glial cells. Secondly, they also demonstrated that neuronal function is disrupted in aged mice (18-20 months of age) lacking Apoe, even in absence of amyloid. They concluded that ApoE has a dual effect with a neurotoxic component during early stages of amyloid brain load and a neuroprotective component in later stages of aging. The effect of lack of murine Apoe in models of amyloidosis has been extensively studied for the past two decades. Several concerns exist about the current study, as described below:</p>
<ol>
<li>
<p>Several studies have shown that Apoe-/-mice exhibit a vascular phenotype including pronounced blood-brain barrier (BBB) leakage of blood-derived molecules, increased BBB permeability to Gadolinium contrast agent, perivascular IgG and fibrinogen deposits, loss of tight junctions, increased MMP-9 cerebrovascular expression, loss of pericytes, basement membrane degeneration, etc. Answer: We did not focus our analysis on the impact of the lack of apoE on the integrity of the neurovasculature, as we primarily analyzed its effect on neuronal function. We agree with the reviewer that apoE has been implicated in the maintenance of the BBB integrity, a function that could definitively contribute to the observed phenotype. Other important roles of apoE in brain lipid metabolism, myelin integrity, neuroinflammation, neuronal response to stress or via its direct interaction with Abeta could participate in apoE-dependent preservation of neuronal function in APP/PS1 mice or loss of neuronal functionality in aged apoE-null mice. The relationship between the vascular anomalies caused by the lack of Apoe and their effect on neuronal and synaptic integrity could potentially be the object of another study.</p>
</li>
<li>
<p>Plasma cholesterol is typically high in Apoe-/-mice. Has the same been observed after global Apoe silencing? Would silencing Apoe in the central nervous system have different effect from global Apoe silencing? Answer: We apologize if our manuscript was not clear enough and the description of the mouse model used in our study confusing. We have actually used mice presenting with a complete knock-down of the murine apoE gene in both the nervous system and the periphery. Unfortunately, no mouse model yet allows to conditionally ablate the apoE gene in the nervous system or the liver independently. We agree that it would be a very powerful approach to be able to do so.</p>
</li>
<li>
<p>How does Apoe genetic ablation rescue synaptic integrity near Abeta plaques? Is this a direct or indirect effect? Investigating some mechanistic aspect would greatly strengthen the present findings.</p>
</li>
</ol>
<p>Answer:</p>
<p>We agree with the reviewer that this is a very interesting finding, especially because previous papers have demonstrated that Apoe may act as a chaperone for the recruitment of Abeta neurotoxic species at the synapse (Koffie RM et al. Brain 2012). Intriguingly, our array tomography data do not show that there is necessarily less Abeta at the synapse, which goes against this initial hypothesis. In our manuscript, we therefore discuss the possibility that the rescue effect toward Abeta-dependent synaptic loss observed in absence of apoE may be due to the fact that the association between Abeta and apoE changes the conformational state of those neurotoxic species and leads to more harmful impact on synapses. In vitro, apoE has been previously shown modulates the formation of neurotoxic Abeta oligomers (Hashimoto T et al. J. Neurosci. 2012), but we have not assessed this phenomenon in the present study.</p>
<ol>
<li>The authors findings show "that the absence of APOE largely abrogates Aβ-dependent neuronal dysfunction in a mouse model of amyloidosis." Other groups have shown that Apoe-/mice have a phenotype with cognitive behavioral deficits and neuronal dysfunction (Nature. 2012 May 16;485(7399):512-6;Front Aging Neurosci. 2016 Nov 29;8:287;Behav Sci (Basel). 2018 Mar 3;8(3)). In the context of ApoE deficiency, how is neuronal function impaired in the absence of Abeta (refs above) and neuronal function improved in the presence of Abeta (authors' findings)? Please expand on this point and include a working model of how ApoE ablation improves specifically Abeta-dependent neuronal dysfunctions.</li>
</ol>
<p>Answer:</p>
<p>The reported cognitive deficits in apoE-deficient animals remain somewhat controversial, as stated in the introduction of our manuscript (a few papers demonstrated cognitive impairment in those mice while others failed to do so: Grootendorst et al., 2008, Hartman, Wozniak et al., 2001. This is exactly why we initiated the present work, so that we could get a better understanding of the impact of the lack of apoE on neuronal function at the level of single cells (using multiphoton calcium imaging) and within a simple neuronal circuit (the visual network). Our findings do not disagree with the above references highlighted by the reviewer. Indeed, we also detected some impairment in the visually-evoked neuronal responses in aged Apoe-null mice, even without any amyloid pathology. In the discussion of our manuscript, we emphasize the possible molecular mechanisms that could explain why the lack of apoE alleviates Abeta-dependent neurotoxicity while at the same time sensitizing the brain to stress in older animals, even without amyloid pathology. 5. The rationale to examine neuronal function and synaptic integrity specifically in the visual cortex should be provided. Does neuronal dysfunction occur in other brain regions relevant to AD pathology?</p>
<p>Answer:</p>
<p>The study of neuronal dysfunction in the visual cortex is relevant to AD, as deficits in central sensory processing have been reported in the disease, particularly at advanced stages (PMID: 19713001, 1996878). In addition, the visual cortex is a convenient model to assess network integrity in vivo because it is easily accessible to perform either electrophysiology recordings or intra-vital calcium imaging (PMID: 22196337). The visual area V1 is also the output of a relatively simple circuitry, downstream of the retina and the lateral geniculate nucleus within the thalamus (PMID: 28772103), therefore facilitating the study of neuronal integration and response to well-controlled sensory stimuli.</p>
<p>We have now modified our manuscript and added this justification for our approach in the first paragraph of the results.</p>
<ol>
<li>Fig.4A: The overall level of Abeta doesn't change in APP/PS1 vs. APP/PS1;Apoenull mice, however the distribution appears different between the groups (larger in diameter/size in</li>
</ol>
<p>(see for example Am. J. Mol. Med. 2001; 7:810-815; Am. J. Physiol. Cell Physiol. 2007; 292:C1256-C1262; Exp Neurol. 2001 May;169(1):13-22; Lab Invest. 2001 Jul;81(7):953-60; J Biol Chem. 2011 May 20;286(20):17536-42; Nature. 2012 May 16;485(7399):512-6; PLoS Biol. 2015 Oct 29;13(10):e1002279; Mol Psychiatry. 2014 Oct;19(10):1143-9; Ann Neurol. 2016 Jan;79(1):144-51; Front Physiol. 2016 Oct 6;7:453). Did the authors observe an effect on cerebral vasculature after genetic ablation of Apoe? Did ApoE loss cause vascular dysfunction in aged mice that could mediate the observed neuronal dysfunction and visually-evoked responses?
Answer:We apologize for this error and have now inserted the correct reference in the manuscript.11. For representative immunostaining images, the panels should indicate synaptic markers (for exampleFig. 5).Answer:We have now indicated in the figure panels the specific pre-and post-synaptic markers used for the array tomography staining.figure legendsto the main manuscript text file and upload the S figures as individual files -please fill in all mandatory fields in our submission system and sign the electronic license to publish form -please link your profile in our submission system to your ORCID iD, you should have received an email with instructions on how to do this.To upload the final version of your manuscript, please log in to your account: https://lsa.msubmit.net/cgi-bin/main.plex You will be guided to complete the submission of your revised manuscript and to fill in all necessary information.To avoid unnecessary delays in the acceptance and publication of your paper, please read the following information carefully.A. FINAL FILES:These items are required for acceptance.--An editable version of the final text (.DOC or .DOCX) is needed for copyediting (no PDFs).--High-resolution figure, supplementary figure and video files uploaded as individual files: See our detailed guidelines for preparing your production-ready images, http://life-sciencealliance.org/authorguide --Summary blurb (enter in submission system): A short text summarizing in a single sentence the study (max. 200 characters including spaces). This text is used in conjunction with the titles of papers, hence should be informative and complementary to the title. It should describe the context and significance of the findings for a general readership; it should be written in the present tense and refer to the work in the third person. Author names should not be mentioned.B. MANUSCRIPT ORGANIZATION AND FORMATTING:Full guidelines are available on our Instructions for Authors page, http://life-sciencealliance.org/authorguideWe encourage our authors to provide original source data, particularly uncropped/-processed electrophoretic blots and spreadsheets for the main figures of the manuscript. If you would like to add source data, we would welcome one PDF/Excel-file per figure for this information. These files will be linked online as supplementary "Source Data" files. <strong>Submission of a paper that does not conform to Life Science Alliance guidelines will delay the acceptance of your manuscript.</strong> <strong>It is Life Science Alliance policy that if requested, original data images must be made available to the editors. Failure to provide original images upon request will result in unavoidable delays in publication. Please ensure that you have access to all original data images prior to final submission.</strong> <strong>The license to publish form must be signed before your manuscript can be sent to production. A link to the electronic license to publish form will be sent to the corresponding author only. Please take a moment to check your funder requirements.</strong> <strong>Reviews, decision letters, and point-by-point responses associated with peer-review at Life Science Alliance will be published online, alongside the manuscript. If you do want to opt out of this transparent process, please let us know immediately.</strong> Thank you for your attention to these final processing requirements. Please revise and format the manuscript and upload materials within 7 days.Thank you for this interesting contribution, we look forward to publishing your paper in Life Science Alliance.Sincerely, Andrea Leibfried, PhD Executive Editor Life Science Alliance Meyerhofstr. 1 69117 Heidelberg, Germany t +49 6221 8891 502 e a.leibfried@life-science-alliance.org The final published version of your manuscript will be deposited by us to PubMed Central upon online publication.Your manuscript will now progress through copyediting and proofing. It is journal policy that authors provide original data upon request.Reviews, decision letters, and point-by-point responses associated with peer-review at Life Science Alliance will be published online, alongside the manuscript. If you do want to opt out of this transparent process, please let us know immediately. <strong><em>IMPORTANT: If you will be unreachable at any time, please provide us with the email address of an alternate author. Failure to respond to routine queries may lead to unavoidable delays in publication.</em></strong> Scheduling details will be available from our production department. You will receive proofs shortly before the publication date. Only essential corrections can be made at the proof stage so if there are any minor final changes you wish to make to the manuscript, please let the journal office know now.DISTRIBUTION OF MATERIALS:Authors are required to distribute freely any materials used in experiments published in Life Science Alliance. Authors are encouraged to deposit materials used in their studies to the appropriate repositories for distribution to researchers.You can contact the journal office with any questions, contact@life-science-alliance.org Again, congratulations on a very nice paper. I hope you found the review process to be constructive and are pleased with how the manuscript was handled editorially. We look forward to future exciting submissions from your lab.</p>            </div>
        </div>

    </div>
</body>
</html>